Hirose T, Kuroda T, Otsuki M, Takagi M, Yamamoto H, Motomura T, Kurebayashi S, Miyashita Y, Koga M, Arita N, Hayakawa T, Kishimoto T, Kasayama S
Department of Medicine III, Osaka University Medical School.
Intern Med. 1997 May;36(5):345-50. doi: 10.2169/internalmedicine.36.345.
A case with diabetes mellitus associated with growth hormone (GH)-producing pituitary adenoma is described. A 56-year-old woman who had been treated for diabetes mellitus for 3 years, was admitted for the treatment of hyperglycemia. She showed a few acromegalic features and her plasma GH level was 146 +/- 16 ng/ml. After improvement of plasma glucose level by insulin injection, octreotide therapy (100 micrograms/8 hours) was started. Seven days after the initiation of octreotide therapy, the fasting plasma glucose level was almost normalized without insulin injection. After the octreotide treatment, urinary C-peptide excretion was significantly decreased and the plasma GH level became within normal range. In this case, octreotide appears to have improved the insulin sensitivity by reducing the plasma GH level.
本文描述了一例糖尿病合并生长激素（GH）分泌型垂体腺瘤的病例。一名56岁女性，患糖尿病3年，因高血糖入院治疗。她有一些肢端肥大症的特征，血浆GH水平为146±16 ng/ml。通过注射胰岛素使血糖水平改善后，开始使用奥曲肽治疗（100微克/8小时）。奥曲肽治疗开始7天后，空腹血糖水平在未注射胰岛素的情况下几乎恢复正常。奥曲肽治疗后，尿C肽排泄显著减少，血浆GH水平恢复至正常范围。在该病例中，奥曲肽似乎通过降低血浆GH水平改善了胰岛素敏感性。
